Michelle Scurr

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

Stefan Sleijfer, Isabelle Ray‐Coquard, Zsuzsa Pápai et al. · Journal of Clinical Oncology · 2009 · 674 citations · Full text

Oncology, Angiogenesis, Bone Sarcoma Group +14

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies

Udai Banerji, Anne O’Donnell, Michelle Scurr et al. · Journal of Clinical Oncology · 2005 · 488 citations · Full text

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

Maria Dêbiec‐Rychter, Herlinde Dumez, Ian Judson et al. · European Journal of Cancer · 2004 · 442 citations

Surgical Oncology, Bone Sarcoma Group, Gastrointestinal Oncology +8

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

David Olmos, Sophie Postel‐Vinay, L Rhoda Molife et al. · The Lancet Oncology · 2009 · 338 citations · Full text

Anti-igf-1r Antibody Figitumumab, Medicine, Immunology +7

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

Ian Judson, Peiming Ma, Bin Peng et al. · Cancer Chemotherapy and Pharmacology · 2004 · 191 citations

Imatinib Pharmacokinetics, Oncology, Bone Sarcoma Group +8